COMMUNIQUÉS West-GlobeNewswire

-
Dyadic to Attend Future Food Tech Event March 21 – 22, 2024 in San Francisco, California
21/03/2024 -
Capricor Therapeutics to Present at Upcoming Investor Conferences
21/03/2024 -
Chromocell Announces Formal Launch of Eye Pain Treatment Program and Hiring of Dr. Simon Chandler
21/03/2024 -
Smart for Life Appoints Nutraceutical Industry Veteran Heather Granato to the Company’s Advisory Board
21/03/2024 -
AiBtl BioPharma Inc. Completes $7.6M Land Deal: Exchanging Stock for Real Estate, Demonstrating the Value of ABVC's 23M AiBtl Share Ownership as Hundred Million Dollars
21/03/2024 -
USDA-APHIS Determines that Yield10 Bioscience’s Omega-3 Camelina Varieties May Be Planted and Bred in the United States
21/03/2024 -
Landos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2023 Results
21/03/2024 -
CMR Surgical announces over 20,000 surgical cases completed using Versius
21/03/2024 -
Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma
21/03/2024 -
Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024
21/03/2024 -
BioStem Technologies to Report Fourth Quarter 2023 Financial Results on Monday, April 01, 2024
21/03/2024 -
CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors
21/03/2024 -
Disc Medicine Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
21/03/2024 -
Acumen Pharmaceuticals to Present Deeper Insights, Including Fluid Biomarker Data for Sabirnetug (ACU193), During Emerging Science Session at the American Academy of Neurology Annual Meeting
21/03/2024 -
Tonix Pharmaceuticals Announces Poster Presentation Describing Discovery of Novel Next-Generation Oxytocin Analogues at the American Chemistry Society (ACS) Spring 2024 Meeting
21/03/2024 -
CAMP4 Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Study of CMP-CPS-001, a Potential First-in-Class Therapeutic for Urea Cycle Disorders
21/03/2024 -
Context Therapeutics Reports Full Year 2023 Operating and Financial Results
21/03/2024 -
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023
21/03/2024 -
Theratechnologies Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
21/03/2024
Pages